Emergent BioSolutions Inc.

EBS

Emergent BioSolutions Inc.

EBS

Insider Sentiment (TTM):

Last Purchase:2025-05-13Last Sale:2026-05-01Shares Purchased (TTM):0Shares Sold (TTM):144,870

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:40,347,616Shares Outstanding:51,900,000Institutional Ownership Pct.:77.74%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	140	160	205	246	267	149	100	150	70	79	112	88
Restricted Cash Current	1	1	4	4	4	4	6	7	1	1	0	-
Accounts Receivable Net Current	190	122	84	150	80	204	155	121	196	234	191	217
Inventory Net	304	328	343	356	339	314	312	323	318	333	329	354
Prepaid Expense And Other Assets Current	25	27	26	26	24	30	27	61	36	37	48	62
Assets Of Disposal Group Including Discontinued Op…	-	-	-	6	6	6	-	-	34	-	-	-
Assets Current	666	638	663	787	720	707	599	661	655	682	680	721
Property Plant And Equipment Net	178	199	205	210	216	221	271	278	306	379	383	395
Intangible Assets Net Excluding Goodwill	262	470	437	453	469	485	502	518	534	550	567	583
Goodwill	-	-	-	-	-	-	0	-	-	-	0	0
Other Assets Noncurrent	11	13	14	12	13	13	19	21	19	191	194	194
Assets	1,117	1,320	1,319	1,461	1,417	1,426	1,390	1,478	1,514	1,804	1,823	1,893
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	50	40	56	57	64	58	61	82	96	100	112	113
Accrued Liabilities Current	17	9	12	14	14	13	18	16	17	14	19	17
Employee Related Liabilities Current	26	22	42	37	32	25	56	63	67	42	74	83
Notes Payable Current	-	-	-	-	-	-	0	1	415	459	414	414
Asset Acquisition Contingent Consideration Liabili…	-	50	-	-	-	-	-	-	-	-	-	-
Contract With Customer Liability Current	15	12	-	-	-	-	-	-	-	-	-	-
Accrued Income Taxes Current	4	7	-	-	-	-	-	-	-	-	-	-
Other Liabilities Current	10	8	16	24	14	11	22	68	15	15	33	38
Liabilities Of Disposal Group Including Discontinu…	-	-	-	5	5	5	-	-	10	-	-	-
Liabilities Current	123	149	132	137	127	112	162	230	620	630	651	664
Long Term Debt Noncurrent	582	574	572	663	668	666	664	662	447	447	447	448
Deferred Income Tax Liabilities Net	35	33	38	36	47	60	42	42	35	35	47	52
Other Liabilities Noncurrent	35	42	54	43	40	35	39	36	26	28	29	31
Liabilities	775	797	796	879	881	873	907	969	1,127	1,140	1,174	1,196
Stockholders Equity
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Value	-271	-262	-253	-244	-235	-228	-228	-228	-228	-228	-228	-228
Additional Paid In Capital	952	945	942	939	935	931	928	924	915	910	904	900
Accumulated Other Comprehensive Income Loss Net Of…	-7	-7	-8	-8	-8	-6	-5	-7	-6	-6	-6	-3
Retained Earnings Accumulated Deficit	-333	-153	-160	-105	-156	-144	-212	-181	-296	-13	-22	28
Stockholders Equity	341	523	523	583	536	553	483	508	386	664	649	697
Liabilities And Stockholders Equity	1,117	1,320	1,319	1,461	1,417	1,426	1,390	1,478	1,514	1,804	1,823	1,893
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	15	15	15	15	15	15	15	15	15	15	15	15
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	62	61	61	61	60	60	60	60	59	58	58	57
Shares Outstanding	51	52	52	53	54	55	54	54	53	52	52	52
Treasury Stock Common Shares	11	10	9	8	7	6	6	6	6	6	6	6

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.24%	-5.55%	-9.92%	-	-	-	-	-	-	-	-	-
2025	-0.63%	-0.16%	12.74%	0.73%	8.13%	18.20%	-21.81%	-3.27%	-14.41%	0.49%	8.10%	-2.58%
2024	44.24%	97.58%	239.39%	45.28%	30.94%	56.12%	-8.00%	-24.82%	6.00%	-27.07%	-14.08%	0.16%
2023	-	-	-	-14.19%	-42.57%	-66.22%	3.77%	-23.58%	59.91%	-5.95%	-28.62%	76.95%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.42	4.29	5.01	5.76	5.66	6.32	3.69	2.88	1.06	1.08	1.04	1.09
Quick Ratio	2.74	1.90	2.22	2.97	2.81	3.24	1.60	1.21	0.49	0.50	0.46	0.46
Working Capital	543.20M	488.90M	530.30M	650.40M	592.40M	594.90M	436.30M	431.50M	34.80M	52.20M	28.20M	56.80M
Leverage & Debt
Debt to Equity	2.27	1.52	1.52	1.51	1.64	1.58	1.88	1.91	2.92	1.72	1.81	1.72
Interest Coverage TTM	-1.30	1.09	1.69	1.99	2.03	-1.61	-1.53	-1.84	-5.03	-5.72	-8.26	-9.39
Debt Ratio	0.69	0.60	0.60	0.60	0.62	0.61	0.65	0.66	0.74	0.63	0.64	0.63
Efficiency & Turnover
Asset Turnover TTM	0.61	0.49	0.55	0.54	0.58	0.60	0.65	0.79	0.71	0.50	0.42	0.43
Days Sales Outstanding TTM	63.93	87.72	58.64	62.65	59.17	82.65	60.42	46.51	68.17	59.95	60.91	72.29
Receivables Turnover TTM	5.71	4.16	6.22	5.83	6.17	4.42	6.04	7.85	5.35	6.09	5.99	5.05
Per Share Metrics
Diluted EPS TTM	-3.43	-0.15	0.93	1.34	2.57	-2.30	-3.60	-3.76	-11.16	-10.83	-14.85	-14.97
Free Cash Flow Per Share TTM	1.66	2.61	2.93	0.03	2.86	1.74	0.68	2.60	0.71	-2.53	-5.04	-4.04
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	55.87%	54.24%	56.09%	54.46%	53.50%	35.24%	34.72%	80.89%	76.39%	82.96%	79.96%	27.70%
Operating Profit Margin TTM	-8.57%	8.97%	13.47%	15.02%	12.51%	-10.21%	-10.42%	-10.79%	-34.53%	-45.47%	-69.23%	-72.42%
Net Profit Margin TTM	-22.96%	-1.27%	7.08%	9.62%	16.38%	-13.63%	-18.26%	-15.75%	-45.08%	-47.69%	-72.48%	-75.71%
Growth Metrics
Net Revenue Growth (1Y)	-9.56%	-29.89%	-28.81%	-40.48%	-34.60%	-18.56%	-0.54%	29.42%	38.55%	13.47%	-6.10%	-42.83%
Net Income Growth (1Y)	-226.74%	-93.47%	-127.60%	-136.35%	-123.76%	-76.72%	-74.94%	-73.07%	-2.02%	43.44%	259.40%	-2,625.73%
EPS Growth (1Y)	-233.12%	-93.15%	-127.34%	-136.28%	-123.06%	-77.66%	-75.79%	-73.73%	-5.56%	37.94%	251.68%	-2,533.09%
Valuation Metrics
P/E TTM	-2.45	-50.09	12.57	6.18	2.48	-2.01	-2.66	-2.12	-0.61	-0.23	-0.16	-0.23
P/B TTM	1.27	0.82	1.27	0.81	0.64	0.48	1.05	0.87	0.93	0.20	0.19	0.25
P/S TTM	0.56	0.64	0.89	0.59	0.41	0.27	0.49	0.33	0.28	0.11	0.12	0.17
Market Cap	432.41M	430.77M	661.26M	469.22M	345.80M	264.38M	506.68M	443.39M	358.73M	132.07M	122.88M	176.12M
Enterprise Value	873.31M	842.87M	1.03B	883.12M	742.60M	777.28M	1.07B	949.59M	1.15B	958.97M	871.38M	950.12M
Calculated Values
Free Cash Flow TTM	85.90M	135.40M	156.80M	1.40M	155.00M	94.40M	35.80M	138.10M	37.60M	-132.20M	-257.90M	-209.40M
Net Debt	440.90M	412.10M	366.70M	413.90M	396.80M	512.90M	564.20M	506.20M	791.20M	826.90M	748.50M	774.00M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-01Sale

Owner: Zoon, Kathryn C

Title: -

Shares: 17,202

Price/Share: $8.66

Value: $148,969.32

Shares Owned: 79,941

Relationship: Director

Ownership: Direct

2026-05-01Sale

Owner: Dayal, Sujata Tyagi

Title: -

Shares: 13,761

Price/Share: $8.65

Value: $119,032.65

Shares Owned: 100,563

Relationship: Director

Ownership: Direct

2026-05-01Sale

Owner: Degolyer, Donald W

Title: -

Shares: 15,481

Price/Share: $8.66

Value: $134,065.46

Shares Owned: 129,721

Relationship: Director

Ownership: Direct

2026-04-30Sale

Owner: Katkin, Keith

Title: -

Shares: 15,481

Price/Share: $8.28

Value: $128,182.68

Shares Owned: 96,294

Relationship: Director

Ownership: Direct

2026-04-01Sale

Owner: Williams, Paul Anthony

Title: SVP, Products Business

Shares: 4,000

Price/Share: $8.44

Value: $33,760.00

Shares Owned: 62,681

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-01	Zoon, Kathryn C	Director	-	Direct	Sale	17,202	8.66	$148,969.32	79,941	4
2026-05-01	Dayal, Sujata Tyagi	Director	-	Direct	Sale	13,761	8.65	$119,032.65	100,563	4
2026-05-01	Degolyer, Donald W	Director	-	Direct	Sale	15,481	8.66	$134,065.46	129,721	4
2026-04-30	Katkin, Keith	Director	-	Direct	Sale	15,481	8.28	$128,182.68	96,294	4
2026-04-01	Williams, Paul Anthony	Officer	SVP, Products Business	Direct	Sale	4,000	8.44	$33,760.00	62,681	4
2025-12-05	Richard, Ronald	Director	-	Direct	Sale	21,984	12.00	$263,808.00	98,417	4
2025-11-10	Degolyer, Donald W	Director	-	Direct	Sale	17,801	10.54	$187,622.54	119,858	4
2025-11-07	Dayal, Sujata Tyagi	Director	-	Direct	Sale	8,552	10.00	$85,520.00	88,980	4
2025-10-07	Glessner, Coleen	Officer	EVP, Quality & Ethics, and CPL	Direct	Sale	30,608	10.00	$306,080.00	144,319	4
2025-08-15	Zoon, Kathryn C	Director	-	Direct	Sale	7,086	8.87	$62,852.82	71,799	4
2025-08-12	Degolyer, Donald W	Director	-	Direct	Sale	7,844	8.65	$67,850.60	137,659	4
2025-05-23	Katkin, Keith	Director	-	Direct	Sale	7,844	6.30	$49,417.20	86,431	4
2025-05-13	Papa, Joseph C	Director,Officer	President and CEO	Direct	Purchase	60,000	5.83	$349,800.00	342,500	4
2025-03-12	Zoon, Kathryn C	Director	-	Direct	Sale	10,000	5.73	$57,300.00	44,482	4
2025-03-12	Fowler, Neal Franklin	Director	-	Direct	Sale	35,000	5.83	$204,050.00	101,100	4
2024-11-12	Degolyer, Donald W	Director	-	Direct	Sale	25,000	10.91	$272,750.00	111,100	4
2024-11-11	White, Marvin L	Director	-	Direct	Sale	14,287	11.97	$171,015.39	54,092	4
2024-06-04	Zoon, Kathryn C	Director	-	Direct	Sale	10,000	6.11	$61,100.00	54,482	4
2024-05-29	Zoon, Kathryn C	Director	-	Direct	Sale	1,830	4.61	$8,436.30	64,482	4
2024-05-21	Zoon, Kathryn C	Director	-	Direct	Sale	1,089	5.78	$6,294.42	48,882	4
2023-06-02	Zoon, Kathryn C	Director	-	Direct	Sale	1,830	8.35	$15,280.50	49,971	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

77.74%

Inst. Shares: 40,347,616

Shares Outstanding: 51,900,000

2025-12-31

76.53%

Inst. Shares: 40,941,208

Shares Outstanding: 53,500,000

2025-09-30

74.34%

Inst. Shares: 39,550,467

Shares Outstanding: 53,200,000

2025-06-30

68.34%

Inst. Shares: 37,042,235

Shares Outstanding: 54,200,000

2025-03-31

61.78%

Inst. Shares: 33,606,654

Shares Outstanding: 54,400,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	40,347,616	51,900,000	77.74%
2025-12-31	40,941,208	53,500,000	76.53%
2025-09-30	39,550,467	53,200,000	74.34%
2025-06-30	37,042,235	54,200,000	68.34%
2025-03-31	33,606,654	54,400,000	61.78%
2024-12-31	33,926,888	53,000,000	64.01%
2024-09-30	30,097,603	53,100,000	56.68%
2024-06-30	29,870,066	52,600,000	56.79%
2024-03-31	34,696,350	52,200,000	66.47%
2023-12-31	39,475,222	51,200,000	77.10%
2023-09-30	40,302,536	51,800,000	77.80%
2023-06-30	44,743,110	50,700,000	88.25%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Emergent BioSolutions Inc. (EBS) — SEC Financial Statements & Analysis

Emergent BioSolutions Inc. (EBS) is a pharmaceutical preparations company, incorporated in DE. Emergent BioSolutions Inc. trades on NYSE as: EBS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Emergent BioSolutions Inc. reported a -9.56% year-over-year revenue growth, a Gross Profit Margin of 55.87% (TTM), a Debt-to-Equity ratio of 2.27x, a Price-to-Sales (P/S) ratio of 0.56x (TTM), a Price-to-Book (P/B) ratio of 1.27x (TTM), at a market cap of $432.41M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -9.56%
Gross Profit Margin TTM: 55.87%
Debt To Equity: 2.27x
P/S TTM: 0.56x
P/B TTM: 1.27x
Market Cap: $432.41M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Emergent BioSolutions Inc. in?

Emergent BioSolutions Inc. (EBS) operates in the Pharmaceutical Preparations industry.

What is EBS's market cap?

Emergent BioSolutions Inc. (EBS) has a market capitalization of $432.41M as of 2026-06-30.

What exchange does EBS trade on?

Emergent BioSolutions Inc. (EBS) trades on the NYSE.

Where is Emergent BioSolutions Inc. incorporated?

Emergent BioSolutions Inc. is incorporated in DE.